title: No reactivation of JCV in bone marrow of follicular lymphoma patients treated front-line with rituximab plus 90y-ibritumomab tiuxetan.
authors.affiliation: Department of Translational Research, University of Pisa, via Paradisa 2, 56124, Pisa, Italy, daniele.focosi@gmail.com.
authors.forename: D
authors.initials: D
authors.lastname: Focosi
authors.forename: L
authors.initials: L
authors.lastname: Macera
authors.forename: E
authors.initials: E
authors.lastname: Ciabatti
authors.forename: S
authors.initials: S
authors.lastname: Galimberti
authors.forename: M
authors.initials: M
authors.lastname: Petrini
authors.forename: A M
authors.initials: AM
authors.lastname: Carella
authors.forename: M
authors.initials: M
authors.lastname: Pistello
authors.forename: L
authors.initials: L
authors.lastname: Ceccherini-Nelli
authors.forename: F
authors.initials: F
authors.lastname: Maggi
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001853:Bone Marrow / Q000821:virology*; D059248:Chemoradiotherapy; D002986:Clinical Trials as Topic; D006801:Humans; D007577:JC Virus / Q000502:physiology*; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy / Q000821:virology*; D027601:Polyomavirus Infections / Q000821:virology*; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D000069283:Rituximab; D014412:Tumor Virus Infections / Q000821:virology*; D014775:Virus Activation; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes; D000069283:Rituximab; C422802:ibritumomab tiuxetan